<DOC>
	<DOCNO>NCT00820326</DOCNO>
	<brief_summary>This study offer new treatment , dolasetron ANZEMET ® , administer intravenous way day 4 day Hospitalization . This study double blind ( neither physician know receive active study drug placebo ) . Randomisation begin study decide whether receive active treatment placebo . This treatment renew one month , 2 month 3 month . If study staff determines eligible decide participate , approximately 6 study visit 9 month . During visit , undergo routine health exam complete different kind questionnaire . Following first period 3 month , agree come back consultation month 4 , month 6 month 12 monitoring evaluate effect treatment .</brief_summary>
	<brief_title>Efficacy Dolasetron Patients With Fibromyalgia</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Dolasetron</mesh_term>
	<criteria>Patients age 18 75 Primitive Fibromyalgia accord ACR criterion Patient respond conventional treatment Women childbearing age use efficace contraception Signed consent Inflammatory rheumatic disease Diseases system : Gougerot Sjögren , polymyositis , vasculitis , Infectious disease : hepatitis B C , lyme disease , HIV , Hypothyroidism , Bone mineral metabolism disorder Disorders cardiac conduction Failure Heart , kidney liver , Patient allergic dolasetron Pregnant nursing woman Women without mean contraception , Age &lt; 18 &gt; 75 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>